Median percentages of CD3⁺CD4⁺and CD3⁺CD8⁺ lymphocytes and the median numbers of CD8⁺CD45RO⁺ and CD8⁺CD45RA⁺ lymphocytes in 43 patients with Ph⁺ ALL enrolled in the GIMEMA LAL2116 D-ALBA protocol during blinatumomab administration. PB samples were tested for the percentage of CD3⁺CD4⁺ (A) and CD3⁺CD8⁺ (B) lymphocytes and the median count of PB CD8⁺CD45RO⁺ (C) and CD8⁺CD45RA⁺ (D) lymphocytes. Samples were collected before starting blinatumomab (T0) and after the first (T1), second (T2), third (T3), fourth (T4), and fifth (T5) cycles. Box plots represent the median (line), interquartile range (box), and minimum and maximum values (whiskers). °Outliers. *P < .05; **P < .01. PB, peripheral blood.